Showing 1 - 12 results of 12 for search 'Berthold A. Nock', query time: 0.04s Refine Results
  1. 1
    Toward Stability Enhancement of NTS<sub>1</sub>R-Targeted Radioligands: Structural Interventions on [<sup>99m</sup>Tc]Tc-DT1

    Toward Stability Enhancement of NTS<sub>1</sub>R-Targeted Radioligands: Structural Interventions on [<sup>99m</sup>Tc]Tc-DT1 by Panagiotis Kanellopoulos, Berthold A. Nock, Eric P. Krenning, Theodosia Maina

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

    Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists by Berthold A. Nock, Panagiotis Kanellopoulos, Lieke Joosten, Rosalba Mansi, Theodosia Maina

    Published 2023-04-01
    Get full text
    Article
  3. 3
    Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

    Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics by Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev, Theodosia Maina, Berthold A. Nock, Anna Orlova

    Published 2023-07-01
    Get full text
    Article
  4. 4
    Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands

    Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands by Panagiotis Kanellopoulos, Aikaterini Kaloudi, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina

    Published 2020-06-01
    Get full text
    Article
  5. 5
    Diagnosis of Prostate Cancer with a Neurotensin–Bombesin Radioligand Combination—First Preclinical Results

    Diagnosis of Prostate Cancer with a Neurotensin–Bombesin Radioligand Combination—First Preclinical Results by Maria Bibika, Panagiotis Kanellopoulos, Maritina Rouchota, George Loudos, Berthold A. Nock, Eric P. Krenning, Theodosia Maina

    Published 2024-09-01
    Get full text
    Article
  6. 6
    Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

    Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology by Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova

    Published 2024-02-01
    Get full text
    Article
  7. 7
    GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

    GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics by Karim Obeid, Panagiotis Kanellopoulos, Ayman Abouzayed, Adam Mattsson, Vladimir Tolmachev, Berthold A. Nock, Theodosia Maina, Anna Orlova

    Published 2024-04-01
    Get full text
    Article
  8. 8
    [<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models

    [<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models by Panagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina

    Published 2020-07-01
    Get full text
    Article
  9. 9
    One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [<sup>99m</sup>Tc]Tc-DB4 and [<sup>111</sup>In]In-SG4 in Mice Treated with Entresto

    One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [<sup>99m</sup>Tc]Tc-DB4 and [<sup>111</sup>In]In-SG4 in Mice Treated with Entresto by Panagiotis Kanellopoulos, Aikaterini Kaloudi, Maritina Rouchota, George Loudos, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina

    Published 2020-11-01
    Get full text
    Article
  10. 10
    Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK<sub>2</sub>R Cancer Theranostic Agents: A Preclinical Study

    Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK<sub>2</sub>R Cancer Theranostic Agents: A Preclinical Study by Berthold A. Nock, Panagiotis Kanellopoulos, Oleg G. Chepurny, Maritina Rouchota, George Loudos, George G. Holz, Eric P. Krenning, Theodosia Maina

    Published 2022-03-01
    Get full text
    Article
  11. 11
    Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability

    Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability by Xabier Guarrochena, Panagiotis Kanellopoulos, Anna Stingeder, Lisa-Maria Rečnik, Irene V. J. Feiner, Marie Brandt, Wolfgang Kandioller, Theodosia Maina, Berthold A. Nock, Thomas L. Mindt

    Published 2024-03-01
    Get full text
    Article
  12. 12
    [<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results

    [<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results by Berthold A. Nock, Panagiotis Kanellopoulos, Euy Sung Moon, Maritina Rouchota, George Loudos, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Prashant Mishra, Parvind Sheokand, Frank Roesch, Theodosia Maina

    Published 2023-02-01
    Get full text
    Article

Search Tools: